PMID- 11685111
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 72
IP  - 8
DP  - 2001 Oct 27
TI  - Complete regression of posttransplant lymphoproliferative disease using partially 
      HLA-matched Epstein Barr virus-specific cytotoxic T cells.
PG  - 1399-402
AB  - BACKGROUND: Adoptive immunotherapy with autologous and donor-derived cytotoxic T 
      lymphocytes (CTL) has recently been used to treat Epstein Barr virus 
      (EBV)-positive posttransplant lymphoproliferative disease (PTLD). METHODS AND 
      RESULTS: We report complete regression of EBV-positive PTLD in an 18-month-old 
      small bowel and liver transplant recipient after one infusion of partially human 
      leukocyte antigen (HLA)-matched EBV-specific CTL grown ex vivo from an EBV 
      seropositive unrelated blood donor. No infusion-related toxicity or evidence of 
      graft-versus-host disease was observed. The tumor showed signs of regression 
      within 1 week and EBV load in peripheral blood dropped to undetectable levels. 
      Limiting dilution analyses (LDA) detected no EBV-specific CTL precursor (CTLp) 
      cells before the infusion, and high numbers of CTLp at 4 hr and 24 hr post-CTL 
      infusion. There was a reversal of the CD4/8 ratio in peripheral blood and an 
      increase in HLA-DR positive CD8 cells. The patient has been in complete remission 
      for 24 months. CONCLUSION: If this success is repeated in more PTLD patients, 
      then stored CTL could be used for antiviral and antitumor therapies in 
      immunocompromised patients.
FAU - Haque, T
AU  - Haque T
AD  - Laboratory for Clinical and Molecular Virology, The University of Edinburgh, 
      Summerhall, Edinburgh EH9 1QH, United Kingdom. t.haque@ed.ac.uk
FAU - Taylor, C
AU  - Taylor C
FAU - Wilkie, G M
AU  - Wilkie GM
FAU - Murad, P
AU  - Murad P
FAU - Amlot, P L
AU  - Amlot PL
FAU - Beath, S
AU  - Beath S
FAU - McKiernan, P J
AU  - McKiernan PJ
FAU - Crawford, D H
AU  - Crawford DH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (HLA-DR Antigens)
SB  - IM
CIN - Transplantation. 2001 Oct 27;72(8):1352-3. PMID: 11685102
MH  - HLA-DR Antigens/genetics
MH  - Hematopoietic Stem Cells/immunology
MH  - Herpesvirus 4, Human/*immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Infant
MH  - Intestine, Small/*transplantation
MH  - Liver Transplantation/*adverse effects
MH  - Lymphoproliferative Disorders/*therapy
MH  - Male
MH  - Postoperative Complications/*therapy
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2001/10/31 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/31 10:00
PHST- 2001/10/31 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/31 10:00 [entrez]
AID - 10.1097/00007890-200110270-00012 [doi]
PST - ppublish
SO  - Transplantation. 2001 Oct 27;72(8):1399-402. doi: 
      10.1097/00007890-200110270-00012.